Bristol-Myers Squibb Company (BMY) Management presents at Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript)Seeking Alpha • 01/04/24
Bristol-Myers Squibb downgraded on mixed sales performance of new products amid loss of exclusivity concernsProactive Investors • 01/03/24
European Medicines Agency Validates Bristol Myers Squibb's Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid TumorsBusiness Wire • 01/02/24
RAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZBBusiness Wire • 12/31/23
Bristol Myers Squibb (BMY) Rises Yet Lags Behind Market: Some Facts Worth KnowingZacks Investment Research • 12/29/23
Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger targetMarket Watch • 12/27/23
Bristol Myers Squibb Buys RayzeBio, Its Second Multibillion-Dollar Deal in DaysInvestopedia • 12/26/23
Bristol Myers Squibb goes back to the acquisition well with $4.1B purchase of RayzeBioProactive Investors • 12/26/23
Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%Investors Business Daily • 12/26/23